.png){kind=icon}
返回
Complement activation and effector pathways in membranous nephropathy
.png){kind=icon}
PRE
AI
DOI：10.1016/j.kint.2023.10.035.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Complement activation has long been recognized as a central feature of membranous nephropathy (MN). Evidence for its role has been derived from the detection of complement products in biopsy tissue and urine from patients with MN and from mechanistic studies primarily based on the passive Heymann nephritis model. Only recently, more detailed insights into the exact mechanisms of complement activation and effector pathways have been gained from patient data, animal models, and in vitro models based on specific target antigens relevant to the human disease. These data are of clinical relevance, as they parallel the recent development of numerous specific complement therapeutics for clinical use. Despite efficient B -cell depletion, many patients with MN achieve only partial remission of proteinuria, which may be explained by the persistence of subepithelial immune complexes and ongoing complement -mediated podocyte injury. Targeting complement, therefore, represents an attractive adjunct treatment for MN, but it will need to be tailored to the specific complement pathways relevant to MN. This review summarizes the different lines of evidence for a central role of complement in MN and for the relevance of distinct complement activation and effector pathways, with a focus on recent developments.
Keyword:
complement
glomerulonephritis
glomerulus
membranous nephropathy
proteinuria
期刊
IF:
12.6
论文数:
1.6W
被引数:
4.8W
机构
引用论文
分享收藏Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.png)
LANCET
LANCETIF88.5
PREAI
分享收藏Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
OAAI
OAAI分享收藏
查看更多内容